Nu-Med Plus Faces Financial Struggles with Zero Revenue and Urgent Funding Needs for Survival

Company Overview
Nu-Med Plus, Inc. (OTCMKTS: NUMD) is a Utah-based company focused on developing, manufacturing, and marketing innovative technologies that utilize nitric oxide in the medical device sector. It primarily aims to create cost-effective delivery systems and formulations for nitric oxide, which has documented therapeutic benefits.

Current Financial Position
As of March 31, 2025, Nu-Med reported total assets of $5,173 and total liabilities of $240,202, resulting in a stockholders' deficit of $235,029. The company has practically no revenue, which has been consistent since its inception.

Income Statement Highlights
For the three months ended March 31, 2025, the income statement presents the following key points:

• Revenue: $0 (no revenue generated)
• Operating Expenses: $18,700, decreased from $20,579 in Q1 2024
• Operating Loss: $(18,700)
• Net Loss: $(19,933), improved from a loss of $(21,826) in Q1 2024
• Basic and Diluted Loss per Share: $(0.00), consistent over years

Positive Aspects:

- Reduction in operating expenses indicates efforts toward cost management with a decrease of $1,879 from the previous year's quarter. - Improvement in net loss, demonstrating a positive trend as the company attempts to streamline expenses.

Negative Aspects:

- Ongoing net loss with no revenue generation highlights significant financial challenges and reliance on external financing. - Current assets are minimal ($5,173) compared to total liabilities ($240,202), indicating financial instability.

Outlook and Challenges
Nu-Med remains in the developmental stage, having suspended product development due to a lack of funding. The company projects the need for approximately $1.2 million within the next 12 months to cover expenses and product development. Without additional capital infusion, there is substantial doubt about the company’s ability to continue its operations and meet its obligations.

Funding Needs:
The company stresses the necessity for $300,000 for corporate overhead and an additional $900,000 for ongoing development activities to push its projects forward.

Conclusion
Nu-Med Plus, Inc. is currently navigating a precarious financial landscape, with zero revenue and significant loss metrics, underscoring the urgency for capital to secure its future operations and long-term growth strategy in medical technologies.